Global /United States /Healthcare /Drug Manufacturers - General /INTI

Inhibitor Therapeutics, Inc.

INTI

• OTCMKTS: INTI • Delayed

0.0900USD 0%

As of 13 June 2026, Inhibitor Therapeutics, Inc. has a market cap of $15.53M USD, ranking #38738 globally and #5121 in the United States. It ranks #3456 in the Healthcare sector, and #1136 in the Drug Manufacturers - General industry.

Global Rank

38738

Country Rank

5121

Sector Rank

3456

Industry Rank

1136

Key Stats

Market Cap

$15.53MUSD

Enterprise Value

$13.22MUSD

Net Income (TTM)

-$3.3MUSD

PB Ratio

-12.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Francis O'Donnell open_in_new

Employees

Founded

1992

Website

inhibitortx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	0.2%	0%	34%	80%	100%	51%	126%	44%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	INTI Inhibitor Therapeutics Inc ISIN: US45720M1053 Shares Out.: Shares Outstanding: 172.574M¹ Shares Float: 74.206M² TV: TradingView: OTC: INTI SA: Stock Analysis: OTC: INTI YF: Yahoo Finance: INTI GF: Google Finance: OTCMKTS: INTI BA: Barron's: INTI MS: Morningstar: PINX: INTI	0.0900 USD	TV: TradingView: OTC: INTI SA: Stock Analysis: OTC: INTI YF: Yahoo Finance: INTI GF: Google Finance: OTCMKTS: INTI BA: Barron's: INTI MS: Morningstar: PINX: INTI

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 5M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 4M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 2M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 2M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 962K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 757K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 2M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 2M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 2M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 1M%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 709K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 698K%	14.6	United Kingdom

chevron_leftBack